Menu Back toInstructors

#24: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment


  • Louis  Garrison, PhD

    Louis Garrison, PhD

    • Professor, Pharmaceutical Outcomes Research and Policy Program
    • University of Washington, United States

    Dr. Garrison is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. He also co-directs the Global Medicines Program in Global Health. From 2007-2009, Dr. Garrison served on the ISPOR Board of Directors. He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements, and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. He is faculty advisor for the UW ISPOR Student Chapter, and is ISPOR President-elect for 2016-17.

  • Jack M. Mycka

    Jack M. Mycka

    • Global President and CEO
    • Medical Marketing Economics LLC (MME), United States

    As MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations.

Contact us

Registration Questions?

Send Email